Lu Y, Zeng J, Yang S, et al. Association between the rs9131 and rs3806792 polymorphisms of the CXCL2 gene and the risk of HBV‐related hepatocellular carcinoma in a Guangxi population. J Clin Lab Anal. 2020;34:e23310 10.1002/jcla.23310

Yu Lu and Jie Zeng are contributed equally to this work and should be considered as co‐first authors.

ALT

:   alanine aminotransferase

ANOVA

:   analysis of variance

AST

:   aspartate aminotransferase

CEU

:   Utah residents with northern and western European ancestry

CHB

:   chronic hepatitis B

CIs
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:   single nucleotide polymorphisms
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1. INTRODUCTION {#jcla23310-sec-0005}
===============

Hepatitis B virus (HBV) infection is a well‐known global public health issue. According to the WHO, more than 20 billion people worldwide have been infected with HBV; among them, approximately 2.57 billion individuals have developed chronic hepatitis for persistent infection with HBV, and 780 000 have died annually from HBV‐related diseases.[^1^](#jcla23310-bib-0001){ref-type="ref"} Of these diseases, hepatocellular carcinoma (HCC) is the most lethal disease caused by HBV infection. China has the highest HCC incidence rate worldwide, containing about 19% of the world population but accounting for more than half of all newly confirmed HCC cases and deaths.[^2^](#jcla23310-bib-0002){ref-type="ref"} Guangxi, a province in western China, has the highest HCC incidence and mortality rate in China, as well as a relatively high prevalence of HBV.[^2^](#jcla23310-bib-0002){ref-type="ref"} It has been widely accepted that chronic HBV infections progress to chronic hepatitis B (CHB), then develop into liver cirrhosis (LC), and finally result in HCC.[^3^](#jcla23310-bib-0003){ref-type="ref"} However, the underlying mechanisms of this progression are still not fully understood. The clearance of HBV depends on an effective host immune response[^4^](#jcla23310-bib-0004){ref-type="ref"}; thus, immune system‐related cytokines and chemokines are believed to have important roles in HBV‐related HCC development.

C‐X‐C motif chemokine ligand 2 (CXCL2), an antimicrobial gene that is part of a chemokine superfamily, is an immune‐related chemokine expressed at sites of inflammation and participates in various inflammatory and immunoregulatory processes. Recent research has proven that CXCL2 plays multiple roles in various cancers, including HCC, cervical cancer, and bladder cancer.[^5^](#jcla23310-bib-0005){ref-type="ref"}, [^6^](#jcla23310-bib-0006){ref-type="ref"}, [^7^](#jcla23310-bib-0007){ref-type="ref"} However, the results remain controversial. A study by Zhang H et al[^5^](#jcla23310-bib-0005){ref-type="ref"} showed that the expression of CXCL2 was elevated in patients with bladder cancer, co‐elevation of the levels of CXCL1 and CXCL8, both of which are NF‐κB--dependent chemokines. Zhang W et al[^6^](#jcla23310-bib-0006){ref-type="ref"} found that A‐kinase--interacting protein 1 is critical in angiogenesis and the growth of cervical cancer. Our previous study also suggested that CXCL2 has a higher expression in their three‐dimensional co‐culture system as well as clinical HCC tissues, and could significantly increase the migration and invasion ability of SMMC7721 cells.[^7^](#jcla23310-bib-0007){ref-type="ref"} Conversely, a recent study by Ding et al[^8^](#jcla23310-bib-0008){ref-type="ref"} demonstrated a significant down‐regulation of CXCL2 expression in 264 clinical HCC samples. Subat et al[^9^](#jcla23310-bib-0009){ref-type="ref"} also found that the expression of CXCL2 was significantly downregulated in HCC tumor tissues in which the regulation mechanism may be controlled by DNA methylation. However, after treatment with a DNA demethylating agent, the expression of CXCL2 in HCC cell lines was significantly elevated; furthermore, tumors with lower CXCL2 expression have significantly fewer multiple tumors than tumors with higher CXCL2 expression.

As reported, numerous studies have suggested that gene polymorphisms play pivotal roles in the development of HBV‐related HCC. For instance, Dai et al[^10^](#jcla23310-bib-0010){ref-type="ref"} found that the rs187238 GG genotype of IL‐18 may increase the risk of HCC in a healthy population and the risk of LC in CHB carriers; Wang et al[^11^](#jcla23310-bib-0011){ref-type="ref"} suggested that a polymorphism in the liver fatty acid binding protein (rs1545224) might increase HCC risk in LC patients; and several SNPs of interferon genes combined with interferon receptor genes, including IFNL4, IFNLR1, IFNA, and IFNAR2, were also proven associated with HBV‐related liver disease in a Han Chinese population.[^12^](#jcla23310-bib-0012){ref-type="ref"} Rs9131 and rs3806792 are two major polymorphisms of CXCL2, with rs9131 being a 3 prime UTR variant and rs3806792 being an upstream transcript variant (<https://www.ncbi.nlm.nih.gov/snp/?term=CXCL2>).[^13^](#jcla23310-bib-0013){ref-type="ref"} So far, the association between SNPs of CXCL2 and the risk of CHB, HBV‐related LC, and HCC has not been indentified, but the relationship between CXCL2 expression and HCC has been reported. Therefore, the aim of the present study was to evaluate whether the rs9131 and rs3806792 gene polymorphisms of CXCL2 in males and females of Guangxi are associated with the risks of CHB, HBV‐related LC, and HCC.

2. MATERIAL AND METHODS {#jcla23310-sec-0006}
=======================

2.1. Participants {#jcla23310-sec-0007}
-----------------

All included participants were Chinese individuals from Guangxi province. The present study was approved by the ethics committee of the First Affiliated Hospital of Guangxi Medical University (Guangxi, China), and we confirmed that all research was performed in accordance with relevant guidelines, with written informed consent obtained from each patients. A total of 425 patients were enrolled in the present study, which comprised of 150 patients with HBV‐related HCC, 137 patients with HBV‐related LC, and 138 patients with CHB. The patients were all enrolled from the First Affiliated Hospital of Guangxi Medical University from June 2017 to February 2018. All patients had confirmed chronic HBV infections for at least 6 months according to seropositive HBsAg, HBcAb, and HBeAg or HBeAb. In addition, CHB was further confirmed with elevated alanine aminotransferase (ALT, \>40 IU/mL) or aspartate aminotransferase (AST, \>40 IU/mL) levels. LC was confirmed according to the typical morphologic results from ultrasonography or computed tomography (CT), combined with laboratory findings. Regarding the patients with HCC, they were diagnosed according to typical cytologic or histological results, or elevated AFP levels (over 400 ng/mL) together with a positive findings on CT or ultrasonography, and only newly diagnosed HCC patients without any other type of cancer were included. For comparison, 147 healthy volunteers who underwent a routine physical examination at the Health Examination Center of the same hospital were randomly selected. None of the healthy subjects had an HBV infection, and all had normal liver functions.

2.2. DNA extraction and SNP genotypes {#jcla23310-sec-0008}
-------------------------------------

Peripheral white blood cell samples from all participants were used in the extraction of DNA with an AxyPrep Blood Genomic DNA Miniprep Kit (Axygen). After extraction, a polymerase chain reaction (PCR) was used to amplify the DNA, with the kit in a total reaction volume of 20 μL. The primers for PCR were TGATAGAGGCTGAGGAATCCAAGA (rs9131‐forward), gggACAGTTACAAAATAGACACACATAC (rs9131‐reverse), CGCCGCTCTCAGAGATACCG (rs3806792‐forward), and CCCTAACTTTCAATCCCAACAACT (rs3806792‐ reverse).

After amplification, SNPs rs9131 and rs3806792 were genotyped using the SNaPshot^TM^ Multiplex Kit (Applied Biosystems) with single‐base extension primers TCTTTACAGTTACAAAATAGACACACATACATTTCCCTGCCGTCACATTGATCT and tCCCTAACTTTCAATCCCAACAACTGAAATGTCTTCCAGAGAAGTAACTCCCCCCGGTA, respectively. Data were collected and analyzed with GeneMarker software (GeneMarker V2.2.0).

2.3. Statistical analysis {#jcla23310-sec-0009}
-------------------------

Statistical differences in continuous variables such as age among all groups were compared by analyses of variance (ANOVA). Then, chi‐square tests and Fisher\'s exact tests were used to analyze categorical variables. The Hardy‐Weinberg equilibrium (HWE) among all groups was first checked with the goodness‐of‐fit chi‐square test. Allele and genotype frequencies of CXCL2 SNPs were calculated in different comparison groups using the chi‐square test or Fisher\'s exact test, when appropriate. Later, binary logistic regression was further performed to evaluate the odds ratios (ORs) and 95% confidence intervals (CIs), and both age and sex status were adjusted to assess the relative risk derived from a particular genotype or allele. As is known to all, HCC rates in males are 2‐4 times higher than females; gender was therefore treated as a possible confounder.[^13^](#jcla23310-bib-0013){ref-type="ref"} Subgroup analyses in different genders were further performed to assess the possible association within them. With regard to the potential linkage disequilibrium (LD) between the two SNPs, quantification was conducted via Shi\'s standardized coefficient D′[^14^](#jcla23310-bib-0014){ref-type="ref"}; haplotypes of the two SNPs and their frequencies were also estimated via the phase program based on a Bayesian algorithm.[^15^](#jcla23310-bib-0015){ref-type="ref"} All statistical analyses were performed with the IBM SPSS Statistics 23.0 (IBM). All significance tests were two‐sided, and only results with *P* \< .05 were considered significant.

3. RESULTS {#jcla23310-sec-0010}
==========

3.1. Demographic characteristics {#jcla23310-sec-0011}
--------------------------------

Baseline sex data were matched among all patients and healthy subjects (*P* \> .05). However, a significant difference in the mean age was observed between CHB group and other groups, and CHB patients were approximately 10 years younger than LC and HCC patients, as well as healthy controls (*P* \< .001). Details are summarized in Table [1](#jcla23310-tbl-0001){ref-type="table"}.

###### 

Basic characteristic of the study population

  Variable             Healthy controls (n = 147)   CHB patients (n = 138)   *P*‐value   LC patients (n = 137)   *P*‐value   HCC patients (n = 150)   *P*‐value
  -------------------- ---------------------------- ------------------------ ----------- ----------------------- ----------- ------------------------ -----------
  Age (y, mean ± SD)   48.23 ± 11.37                39.71 ± 11.69            \<.001      47.04 ± 11.30           \<.371      50.53 ± 10.35            .076
  Gender, N (%)                                                                                                                                       
  Male                 121 (0.82)                   108 (0.78)               .390        108 (0.79)              .458        127 (0.85)               .585
  Female               26 (0.18)                    30 (0.22)                            29 (0.21)                           23 (0.15)                 
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3.2. Association between CXCL2 SNPs and the risk of HBV‐related HCC {#jcla23310-sec-0012}
-------------------------------------------------------------------

The genotype and allele distribution of the rs9131 and rs3806792 CXCL2 SNPs among CHB, LC, HCC, and healthy subjects are present in Table [2](#jcla23310-tbl-0002){ref-type="table"}. As revealed by the Hardy‐Weinberg equilibrium test results for the two SNPs, the genotype frequencies of these four groups were all in accordance with the prediction of HWE (*P* \> .05). However, significant differences were not observed in the allele frequency or in the genotype distribution of the rs9131 and rs3806792 CXCL2 SNPs and the risk of CHB. After adjusting for age and sex, a significant difference was also failed to be found between them. With respect to the LC and HCC group, similar nonsignificant findings were also revealed. When subgroup analyses were performed in males and females, significant differences were not observed in any of the three groups, including the CHB, LC, and HCC groups. Details are present in Table [3](#jcla23310-tbl-0003){ref-type="table"} and Table [S1](#jcla23310-sup-0001){ref-type="supplementary-material"}.

###### 

Genotype and allele frequencies of rs9131 and rs3806792 SNPs between HBV‐related patients and healthy controls

+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| Polymorphisms                                             | Healthy controls, N = 147 | CHB patients | LC patients, N = 137 | HCC patients, N = 150 | CHB patients vs. Healthy controls | LC patients vs Healthy controls | HCC patients vs Healthy controls |
|                                                           |                           |              |                      |                       |                                   |                                 |                                  |
|                                                           |                           | N = 138      |                      |                       |                                   |                                 |                                  |
+===========================================================+===========================+==============+======================+=======================+===================================+=================================+==================================+
| rs9131                                                    |                           |              |                      |                       |                                   |                                 |                                  |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| CC                                                        | 77 (0.52)                 | 70 (0.51)    | 67 (0.49)            | 69 (0.46)             | 1.00                              | 1.00                            | 1.00                             |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| CT                                                        | 57 (0.39)                 | 60 (0.43)    | 55 (0.40)            | 65 (0.43)             | 1.14 (0.68‐1.92)                  | 1.10 (0.67‐181)                 | 1.26 (0.78‐2.05)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| TT                                                        | 13 (0.09)                 | 8 (0.06)     | 15 (0.11)            | 16 (0.11)             | 0.84 (0.31‐2.23)                  | 1.33 (0.59‐3.00)                | 1.36 (0.61‐3.05)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| Dominant model[^b^](#jcla23310-note-0003){ref-type="fn"}  | 70 (0.48)                 | 68 (0.49)    | 70 (0.51)            | 81 (0.54)             | 1.09 (0.66‐1.79)                  | 1.14 (0.72‐1.82)                | 1.28 (0.81‐2.02)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| Recessive model[^c^](#jcla23310-note-0004){ref-type="fn"} | 134 (0.91)                | 130 (0.94)   | 122 (0.89)           | 134 (0.89)            | 0.79 (0.30‐2.04)                  | 1.28 (0.58‐2.80)                | 1.23 (0.57‐2.66)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| C allele                                                  | 211 (0.72)                | 200 (0.73)   | 189 (0.69)           | 203 (0.68)            | 1.00                              | 1.00                            | 1.00                             |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| T allele                                                  | 83 (0.28)                 | 76 (0.28)    | 85 (0.31)            | 97 (0.32)             | 1.01 (0.69‐1.49)                  | 1.14 (0.79‐1.64)                | 1.21 (0.85‐1.72)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| *P*‐~HWE~                                                 | .601                      | .293         | .468                 | .905                  |                                   |                                 |                                  |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| rs3806792                                                 |                           |              |                      |                       |                                   |                                 |                                  |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| TT                                                        | 76 (0.52)                 | 70 (0.51)    | 67 (0.49)            | 69 (0.46)             | 1.00                              | 1.00                            | 1.00                             |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| TC                                                        | 53 (0.36)                 | 59 (0.43)    | 55 (0.40)            | 64 (0.43)             | 1.21 (0.71‐2.05)                  | 1.17 (0.71‐1.94)                | 1.31 (0.80‐2.14)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| CC                                                        | 18 (0.12)                 | 9 (0.07)     | 15 (0.11)            | 17 (0.11)             | 0.61 (0.25‐1.50)                  | 0.94 (0.44‐2.01)                | 1.06 (0.50‐2.22)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| Dominant model[^d^](#jcla23310-note-0005){ref-type="fn"}  | 71 (0.48)                 | 68 (0.49)    | 70 (0.51)            | 81 (0.54)             | 1.06 (0.64‐1.74)                  | 1.11 (0.70‐1.78)                | 1.25 (0.79‐1.97)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| Recessive model[^e^](#jcla23310-note-0006){ref-type="fn"} | 129 (0.88)                | 129 (0.93)   | 122 (0.89)           | 133 (0.89)            | 0.56 (0.23‐1.33)                  | 0.88 (0.42‐1.82)                | 0.936 (0.46‐1.90)                |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| T allele                                                  | 205 (0.70)                | 199 (0.72)   | 189 (0.69)           | 202 (0.74)            | 1.00                              | 1.00                            | 1.00                             |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| C allele                                                  | 89 (0.30)                 | 77 (0.28)    | 85 (0.31)            | 98 (0.36)             | 0.92 (0.63‐1.35)                  | 1.03 (0.72‐1.47)                | 1.12 (0.79‐1.58)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+
| *P*‐~HWE~                                                 | .077                      | .461         | .468                 | .712                  |                                   |                                 |                                  |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+-----------------------------------+---------------------------------+----------------------------------+

Adjusted by age and gender.

Dominant model: TT + CT vs CC.

Recessive model: TT vs CT + CC.

Dominant model: CT + CC vs TT.

Recessive model: CC vs TT + CT.
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###### 

Genotype and allele frequencies of rs9131 and rs3806792 SNPs between HBV‐related patients and healthy controls in males

+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+----------------------------------+---------------------------------+----------------------------------+
| Polymorphisms                                             | Healthy controls, N = 121 | CHB patients | LC patients, N = 108 | HCC patients, N = 127 | CHB patients vs Healthy controls | LC patients vs Healthy controls | HCC patients vs Healthy controls |
|                                                           |                           |              |                      |                       |                                  |                                 |                                  |
|                                                           |                           | N = 108      |                      |                       |                                  |                                 |                                  |
+===========================================================+===========================+==============+======================+=======================+==================================+=================================+==================================+
| rs9131                                                    |                           |              |                      |                       |                                  |                                 |                                  |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+----------------------------------+---------------------------------+----------------------------------+
| CC                                                        | 63 (0.52)                 | 54 (0.50)    | 52 (0.48)            | 58 (0.46)             | 1.00                             | 1.00                            | 1.00                             |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+----------------------------------+---------------------------------+----------------------------------+
| CT                                                        | 47 (0.39)                 | 47 (0.44)    | 46 (0.43)            | 54 (0.43)             | 1.22 (0.66‐2.27)                 | 1.08 (0.62‐1.90)                | 1.25 (0.74‐2.13)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+----------------------------------+---------------------------------+----------------------------------+
| TT                                                        | 11 (0.09)                 | 7 (0.06)     | 10 (0.09)            | 15 (0.12)             | 1.04 (0.34‐3.19)                 | 1.09 (0.42‐2.81)                | 1.50 (0.63‐3.53)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+----------------------------------+---------------------------------+----------------------------------+
| Dominant model[^b^](#jcla23310-note-0008){ref-type="fn"}  | 58 (0.48)                 | 54 (0.50)    | 56 (0.52)            | 69 (0.54)             | 1.19 (0.66‐2.16)                 | 1.09 (0.64‐1.85)                | 1.30 (0.79‐2.14)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+----------------------------------+---------------------------------+----------------------------------+
| Recessive model[^c^](#jcla23310-note-0009){ref-type="fn"} | 110 (0.91)                | 101 ((0.94)  | 98 (0.91)            | 112 (0.88)            | 0.95 (0.32‐2.78)                 | 1.05 (0.42‐2.62)                | 1.35 (0.59‐3.07)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+----------------------------------+---------------------------------+----------------------------------+
| C allele                                                  | 173 (0.71)                | 155 (0.72)   | 150 (0.69)           | 170 (0.67)            | 1.00                             | 1.00                            | 1.00                             |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+----------------------------------+---------------------------------+----------------------------------+
| T allele                                                  | 69 (0.29)                 | 61 (0.28)    | 66 (0.31)            | 84 (0.33)             | 1.10 (0.70‐1.74)                 | 1.06 (0.70‐1.60)                | 1.25 (0.85‐1.83)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+----------------------------------+---------------------------------+----------------------------------+
| rs3806792                                                 |                           |              |                      |                       |                                  |                                 |                                  |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+----------------------------------+---------------------------------+----------------------------------+
| TT                                                        | 62 (0.51)                 | 54 (0.50)    | 52 (0.48)            | 58 (0.46)             | 1.00                             | 1.00                            | 1.00                             |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+----------------------------------+---------------------------------+----------------------------------+
| TC                                                        | 44 (0.36)                 | 46 (0.43)    | 46 (0.43)            | 53 (0.42)             | 1.28 (0.68‐2.39)                 | 1.14 (0.65‐2.02)                | 1.29 (0.75‐2.21)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+----------------------------------+---------------------------------+----------------------------------+
| CC                                                        | 15 (0.12)                 | 8 (0.07)     | 10 (0.09)            | 16 (0.13)             | 0.78 (0.28‐2.14)                 | 0.77 (0.31‐1.87)                | 1.17 (0.53‐2.57)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+----------------------------------+---------------------------------+----------------------------------+
| Dominant model[^d^](#jcla23310-note-0010){ref-type="fn"}  | 59 (0.49)                 | 54 (0.50)    | 56 (0.52)            | 69 (0.54)             | 1.15 (0.64‐2.08)                 | 1.05 (0.62‐1.78)                | 1.26 (0.76‐2.07)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+----------------------------------+---------------------------------+----------------------------------+
| Recessive model[^e^](#jcla23310-note-0011){ref-type="fn"} | 106 (0.88)                | 100 (0.93)   | 98 (0.91)            | 111 (0.87)            | 0.69 (0.26‐1.83)                 | 0.72 (0.31‐1.70)                | 1.04 (0.49‐2.21)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+----------------------------------+---------------------------------+----------------------------------+
| T allele                                                  | 168 (0.69)                | 154 (0.71)   | 150 (0.69)           | 169 (0.67)            | 1.00                             | 1.00                            | 1.00                             |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+----------------------------------+---------------------------------+----------------------------------+
| C allele                                                  | 74 (0.31)                 | 62 (0.29)    | 66 (0.31)            | 85 (0.33)             | 1.00 (0.64‐1.57)                 | 0.95 (0.64‐1.43)                | 1.15 (0.79‐1.68)                 |
+-----------------------------------------------------------+---------------------------+--------------+----------------------+-----------------------+----------------------------------+---------------------------------+----------------------------------+

Adjusted by age.

Dominant model: TT + CT vs CC.

Recessive model: TT vs CT + CC.

Dominant model: CT + CC vs TT.

Recessive model: CC vs TT + CT.
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Considering that the genetic background of CXCL2 may differ among various ethnicities, the distribution of genotypes and alleles of rs9131 and rs3806792 SNPs was further compared with those in different ethnicities from the 1000 Genomes Project (<https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/>).[^16^](#jcla23310-bib-0016){ref-type="ref"} According to the results in Table [4](#jcla23310-tbl-0004){ref-type="table"}, excluding Han Chinese in Beijing (HCB), the distributions of both rs9131 and rs3806792 in our study are dramatically different from that in Utah residents with northern and western European ancestry (CEU), Gujarati Indian from Houston, Texas (GIH), Japanese in Tokyo, Japan (JPT), and Yoruba in Ibadan, Nigeria (YRI) (all *P* \< .05). For rs9131, the distributions of the C allele and CC genotype in CEU, GIH, and JPT individuals were statistically lower than those in our healthy subjects, while the frequencies of allele T and genotype TT were significantly higher. As for rs3806792, significantly lower frequencies of the allele T and genotype TT, as well as higher frequencies of the allele C and genotype CC in the CEU, GIH, and JPT populations, were found when compared with our control participants.

###### 

Comparison of genotype and allele frequencies in the healthy control subjects of our study and that from the 1000 genomes

  Polymorphisms   Samples, N   Genotype frequency, n   *P* values   Alleles frequency, n   *P* values                             
  --------------- ------------ ----------------------- ------------ ---------------------- ------------ ------------ ------------ ------------
  rs9131                                                                                                                          
  Present study   147          77 (0.52)               57 (0.39)    13 (0.09)                           211 (0.72)   83 (0.28)     
  CEU             99           12 (0.12)               49 (0.49)    38 (0.38)              **\<.001**   73 (0.37)    125 (0.63)   **\<.001**
  HCB             103          45 (0.44)               46 (0.45)    12 (0.12)              .382         136 (0.66)   70 (0.34)    .170
  GIH             103          11 (0.11)               57 (0.55)    35 (0.34)              **\<.001**   79 (0.38)    127 (0.62)   **\<.001**
  JPT             104          26 (0.25)               57 (0.55)    21 (0.20)              **\<.001**   109 (0.52)   99 (0.48)    **\<.001**
  YRI             108          80 (0.74)               24 (0.22)    4 (0.04)               **.002**     184 (0.85)   32 (0.15)    **\<.001**
  rs3806792                                                                                                                       
  Present study   147          18 (0.12)               53 (0.36)    76 (0.52)                           89 (0.30)    205 (0.70)    
  CEU             99           39 (0.39)               49 (0.49)    11 (0.11)              **\<.001**   127 (0.64)   71 (0.36)    **\<.001**
  HCB             103          13 (0.13)               45 (0.44)    45 (0.44)              .425         71 (0.34)    135 (0.66)   .322
  GIH             103          36 (0.35)               59 (0.57)    8 (0.08)               **\<.001**   131 (0.64)   75 (0.36)    **\<.001**
  JPT             104          21 (0.20)               57 (0.55)    26 (0.25)              **\<.001**   99 (0.48)    109 (0.52)   **\<.001**
  YRI             108          4 (0.04)                24 (0.22)    80 (0.74)              **.001**     32 (0.15)    184 (0.85)   **\<.001**

Abbreviations: CEU, Utah residents with northern and western European ancestry; GIH, Gujarati Indian from Houston, Texas; HCB, Han Chinese in Beijing, China; JPT, Japanese in Tokyo, Japan; YRI, Yoruba in Ibadan, Nigeria.

Bold indicates *P*\<.001.
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3.3. Haplotype analysis of the CXCL2 SNPs and HBV‐related diseases risk {#jcla23310-sec-0013}
-----------------------------------------------------------------------

Haplotype analyses were carried out in all four patient and healthy groups with the SHEsis software, and all four possible haplotypes were observed. Overall, in all three comparisons (ie, the CHB group vs the healthy group, the LC group vs the healthy group, and the HCC group vs. the healthy group), a strong linkage disequilibrium was found between the alleles of the rs9131 and rs3806792 SNPs, D\' = 0.991, D\' = 0.991, D\' = 0.992, respectively. According to the results, the C^9131^C^3806792^ haplotype was the major haplotype and accounted for \>65% in all four groups, and the T^9131^T^3806792^ was the second highest haplotype, accounting for 28%‐32% among all groups. However, after haplotype analyses were conducted, significant differences in the distribution of these haplotypes were not observed in any group. The C^9131^T^3806792^ and T^9131^C^3806792^ haplotypes were rare, accounting for \<2% in all groups, so further analyses were therefore not conducted between them. Data are showed in Table [5](#jcla23310-tbl-0005){ref-type="table"}.

###### 

Frequencies of the haplotypes formed by rs9131 and rs3806792 SNPs in HBV‐related patients and healthy controls

  Haplotype   Healthy control   CHB patients   OR (95% CI)        *P*   LC patients   OR (95% CI)        p      HCC patients   OR (95% CI)        *P*
  ----------- ----------------- -------------- ------------------ ----- ------------- ------------------ ------ -------------- ------------------ -----
  CC          204 (0.69)        199 (0.72)     1.05 (0.73‐1.52)   .79   189 (0.69)    0.89 (0.62‐1.28)   0.54   202 (0.67)     0.84 (0.59‐1.19)   .32
  CT          7 (0.02)          1 (0.004)      --                 --    0             --                        1 (0.003)                          
  TC          1 (0.003)         0 (0.00)       --                 --    0             --                        0 (0.00)                           
  TT          82 (0.28)         76 (0.28)      0.95 (0.66‐1.37)   .79   85 (0.31)     1.19 (0.78‐1.61)   0.54   97 (0.32)      1.20 (0.84‐1.70)   .32

John Wiley & Sons, Ltd

4. DISCUSSION {#jcla23310-sec-0014}
=============

HBV infection, for which China accounts for the highest incidence worldwide, is the most common risk factor for the progression of HCC.[^16^](#jcla23310-bib-0016){ref-type="ref"} However, the clinical manifestations of HBV infections vary significantly among individuals, most of them are transient infections, and then are asymptomatic carriers with normal liver histology, the most severe symptoms are persistent carriers with chronic liver diseases such as LC and HCC.[^17^](#jcla23310-bib-0017){ref-type="ref"} And among the subjects persistently infected with HBV, only 10%‐30% will develop LC and HCC.[^18^](#jcla23310-bib-0018){ref-type="ref"} The mechanisms of these highly diverse disease outcomes can only be partially explained by the differences in HBV viral infection, dietary aflatoxin exposure, or other environmental risk factors.[^19^](#jcla23310-bib-0019){ref-type="ref"} Thus, individuals\' genetic background and immunological status may play pivotal roles in such progression.[^20^](#jcla23310-bib-0020){ref-type="ref"}

Chemokines, which are structurally related molecules, are members of a subfamily of homologous proteins.[^21^](#jcla23310-bib-0021){ref-type="ref"} Through chemical interactions, they can regulate the trafficking of multiple types of leukocytes. Furthermore, by recruiting and activating leukocytes, as well as regulating the roles played by T lymphocytes, chemokines have long been considered as crucial mediators in the homeostasis, development, and function of the innate and adaptive immune system.[^22^](#jcla23310-bib-0022){ref-type="ref"} As a member of this chemokines family, CXCL2 has also been shown to be essential for the pathogenesis of HBV‐related HCC; however, it remains a question whether the SNPs of CXCL2 play roles in such progression.

Our present study answered this question by evaluating the association between two major SNPs of CXCL2 and subjects with CHB, LC, and HCC, respectively. However, according to our results, no associations between CXCL2 genotypes, alleles, or haplotypes and the risk of CHB, LC, or HCC were observed; similarly, significant associations were not found when subgroup analyses were conducted in males and females. All these findings indicated that the SNPs of CXCL2 may not be associated with the pathogenesis of HBV‐related HCC. In fact, little research has been conducted on correlations between CXCL2 and cancer, although numerous studies have suggested an association between the polymorphisms occurring in other chemokine genes and cancers. For instance, in CXCL10, a chemokine that serve as a T lymphocyte recruiter, the distributions of the G allele and GG genotype in the rs4508917 polymorphism of CXCL10 were dramatically higher in patients with breast cancer (BC) than in healthy volunteers.[^23^](#jcla23310-bib-0023){ref-type="ref"} And CCL22, acting as a chemoattractant, mediated the intratumoral Treg migration, and the distribution of C allele and CC genotype at rs223818 of this gene was significantly higher in individuals with BC when compared to healthy controls.[^24^](#jcla23310-bib-0024){ref-type="ref"} A CXCL12 G801A polymorphism was also found to be a low penetrance risk factor for the progression of colorectal cancer and was further confirmed to be associated with the T stage of colorectal cancer.[^25^](#jcla23310-bib-0025){ref-type="ref"} It is noteworthy that in our study, when we compared the genotype and allele distributions in healthy subjects to those from the 1000 Genomes Project, a significant difference was found in the CXCL2 genetic background among those ethnicities. In our study, the frequencies of the genotype and allele (CC and C for rs9131 and TT and T for rs3806792) of the two SNPs of CXCL2 in our healthy controls were only similar with those in HCB, but were significantly higher than individuals of other ethnicities, including CEU, GIH, and JPT populations. These data indicate that SNPs rs9131 and rs3806792 of CXCL2 may not be associated with the pathogenesis of HBV‐related HCC in the Chinese population but may play a role in other ethnicities. Another possible explanation for the current nonsignificant results is the limited sample size, given that the strength of an association between a certain polymorphism and a disease partially depends on the sample size achieved. Therefore, further investigations with larger populations with various ethnicities are warranted.

In sum, the present study did not find any effect of genetic polymorphisms between the CXCL2 gene and CHB, HBV‐related LC, or HCC in a Guangxi population. However, the current study had some limitations. First, the present study used a relatively small sample and limited population to assess the relationship between CXCL2 SNPs and HBV‐related diseases; second, only two sites of CXCL2 polymorphisms were assessed; and third, whether the SNPs of rs9131 and rs3806792 reflect the expression of CXCL2 remains unclear, and that may be the possible mechanism for the current nonsignificant results. Therefore, further larger and multicenter research with other SNPs of CXCL2 and their serum levels should be conducted to confirm our findings.
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